Latest news
Lyell Immunopharma reports Q2 2026 net loss $44.8M, cash $228.0M; clinical milestones advance - TradingViewTradingView · Thu, 06 Aug 2026 20:35:29 GMTLyell Immunopharma Reports Business Highlights and Financial Results for the Second Quarter 2026 - GlobeNewswireGlobeNewswire · Thu, 06 Aug 2026 20:05:00 GMTLyell Immunopharma (NASDAQ:LYEL) Earns Buy Rating from Analysts at Stifel Nicolaus - MarketBeatMarketBeat · Thu, 06 Aug 2026 13:40:43 GMTLyell Immunopharma (LYEL) Projected to Post Quarterly Earnings on Tuesday - MarketBeatMarketBeat · Tue, 04 Aug 2026 16:56:39 GMTLyell Immunopharma, Inc. (LYEL) holder pays broker with 44,000 shares - Stock TitanStock Titan · Mon, 27 Jul 2026 07:00:00 GMT